Johnson & Johnson Stock Deutsche Boerse AG

Equities

JNJ0

CA47817E1034

Pharmaceuticals

Market Closed - Deutsche Boerse AG 02:11:39 2024-05-13 EDT 5-day change 1st Jan Change
13.3 EUR 0.00% Intraday chart for Johnson & Johnson +0.76% -2.92%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 88.37B 81.91B 121B Sales 2025 * 90.78B 84.14B 124B Capitalization 361B 334B 493B
Net income 2024 * 22.04B 20.43B 30.12B Net income 2025 * 23.09B 21.4B 31.56B EV / Sales 2024 * 4 x
Net cash position 2024 * 7B 6.49B 9.56B Net cash position 2025 * 21.07B 19.53B 28.8B EV / Sales 2025 * 3.74 x
P/E ratio 2024 *
16.7 x
P/E ratio 2025 *
15.7 x
Employees 131,900
Yield 2024 *
3.22%
Yield 2025 *
3.36%
Free-Float 77.07%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Johnson & Johnson

1 week+0.76%
Current month+1.53%
3 months-10.14%
6 months+0.76%
Current year-2.92%
More quotes
1 week
13.20
Extreme 13.2
13.80
1 month
13.00
Extreme 13
13.80
Current year
13.00
Extreme 13
15.00
1 year
13.00
Extreme 13
15.18
3 years
13.00
Extreme 13
15.18
5 years
13.00
Extreme 13
15.18
10 years
13.00
Extreme 13
15.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change
24-05-13 13.3 0.00%
24-05-10 13.3 -3.62%
24-05-09 13.8 +4.55%
24-05-08 13.2 0.00%
24-05-07 13.2 0.00%

Delayed Quote Deutsche Boerse AG, May 13, 2024 at 02:11 am

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
149.9 USD
Average target price
173.3 USD
Spread / Average Target
+15.58%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW